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Case Report
Linking opioid-induced hyperalgesia and
withdrawal-associated injury site pain:
a case report
Launette Marie Rieba,*, Wendy V. Normana, Ruth Elwood Martina,b, Jonathan Berkowitzc, Evan Woodd,e,
Michael John Milloyd,e, Ryan McNeild,e
Abstract
Introduction and objectives: Understanding the details of one individual’s experience with pain, opioid use and withdrawal may
generate insights into possible relationships between opioid-induced hyperalgesia and withdrawal-associated injury site pain (WISP).
Methods: This case study was extracted from a mixed methods study that characterized WISP. In 2014, the individual was
recruited from a primary care clinic that prescribes opioid agonist therapy. In an interview, she completed a 35-item survey and
elaborated on her own experience. Follow-up contact was made in June of 2017.
Results: This 34-year-old white woman had several twisting injuries of her right knee between ages 13 and 15. The pain resolved
each time in a few days, and she was pain free for 15 years. Around age 30, she initiated illicit oxycodone recreationally (not for pain)
and developed an opioid use disorder. On detoxification, she experienced severe knee pain for 6 weeks that resolved
postdetoxification but returned after subsequent oxycodone use and withdrawal episodes along with generalized skin sensitivity.
This experience of WISP became a barrier to opioid cessation. Although nonsteroidal anti-inflammatories and gabapentin relieved
WISP andmethadone therapy assisted her opioid use disorder, an eventual change to sublingual buprenorphine/naloxone provided
superior control of both.
Conclusion: This case report illustrates that both opioid use and withdrawal can reactivate injury site pain, which can increase with
dose escalation and repeated withdrawal events. The timing, trajectory, and neuropathic features of WISP reported here are
consistent with those previously reported for the development of opioid-induced hyperalgesia, possibly linking these phenomena.
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1. Introduction
As the opioid crisis continues in North America, clinicians and
researchers need to understand factors that perpetuate opioid
use and barriers to detoxification.2,4,19,32,33 There is a growing
body of evidence that opioids can provide a pronociceptive force
both centrally and peripherally, resulting in opioid-induced
hyperalgesia (OIH).13,20,21,28 When regular opioid use is stopped,
some people experience a temporary return of pain at old healed
injury sites, a phenomenon that we have documented and
termed withdrawal-associated injury site pain (WISP).27 The
current case study is the first to detail one individual’s pain
experience with opioid use and withdrawal to shed light on the
possible relationship between OIH and WISP, as well as to
provide a case example to assist in the identification of this
phenomenon.
2. Methods
This case study was extracted from our mixed methods study
that characterized WISP.27 The participant was recruited in 2014
from a primary care clinic providing methadone treatment in
Vancouver, Canada. She providedwritten informed consent. She
screened positive for WISP as per the published protocol and
completed the 35-question survey as well as elaborated on her
own experience in an in-depth interview, whichwas recorded and
transcribed. The initial study protocol was approved by the
Behavioral Research Ethics Board at the University of British
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Columbia and the Vancouver Coastal Health Research Ethics
Board. In June of 2017, the participant was contacted again. She
endorsed a draft of this case report provided to her, and through
email and text provided a brief update of her pain and treatment
experience in the intervening 3 years.
3. Results
A 34-year-old white woman (pseudonym “Alice”) reported
experiencing several twisting injuries of her right knee playing
sports between the ages of 12 and 15. The original injury site pain
(recalled as 4/10 on a 0–10 scale) associated with these injuries
resolved in 2 to 3 days each time. She reported no knee pain,
although an occasional click, for the subsequent 15 years and
was medication free. At age 30, Alice began insufflating illicit
oxycodone recreationally (not for pain) and developed an opioid
use disorder (OUD).
In 2012, at age 32, she abruptly stopped the use of oxycodone
150mg/d, morphine equivalent daily dose (MEDD) 225 mg (1:1.5
oral dose conversion chosen because of conflicting information
regarding intranasal bioavailability).18,22,30 Alice reported experi-
encing moderate generalized withdrawal symptoms along with
severe right knee pain (ie, WISP intensity 8/10 for 30 days, then
4/10 for 15 days). Subsequently, she reported being pain free for
7 months while opioid abstinent. Alice then reinitiated oxycodone
insufflation and found that her right knee pain returned. She
perceived escalation of injury site pain as her dose of opioids
increased and attributed the etiology of the pain to a presumed
chronic knee problem but wondered whether oxycodone was
playing a role. Notably, each subsequent attempt at opioid
cessation produced even greater right knee WISP (intensity
10/10) and generalized skin sensitivity, towards which she
developed fear and aversion. By contrast, opioid withdrawal pain
in the contralateral knee was mild (intensity 2/10) and not always
present when opioids were stopped.
Alice cited WISP as a barrier to detoxification and opioid
cessation. Despite many attempts at opioid cessation in the
previous 2 years, she was able to go beyond the full 6 weeks of
WISP symptoms only 3 times. On each of these 3 occasions, her
right knee pain resolved completely. General withdrawal symp-
toms were a contributor to reinitiation of opioid use but were
typically less intense (4/10) and somewhat shorter than WISP (30
days).
Alice reported that naproxen, ibuprofen, gabapentin, acet-
aminophen, and phenobarbital all diminished WISP somewhat
during acute detoxification. She eventually tried detoxification
with prescribed methadone (ie, 30-mg initial dose, then tapered
by 5mg/d), which easedWISP comparedwith withdrawal with no
medication. At the time of the initial interview in 2014 at age 34,
she was embarking on methadone maintenance treatment and
had recently achieved a dose of 85 mg/d. Yet, she continued to
use oxycodone for knee pain approximately 20 to 40 mg/d,
ostensibly until her methadone dose could be further increased.
At that point, the MEDD was 436 mg (1:4.6 conversion
methadone to morphine and 1:1.5 oxycodone to morphine).22
Alice’s key individual quotes related to her clinical presentation
are found in Table 1.
In follow-up at age 37, Alice related that her methadone had
gone as high as 200 mg per day in the past year (MEDD 920
mg).22 Although methadone had helped her not use illicit opioids,
it had been overly sedating and never managed her knee pain
well. So, in the previous months, she had tapered down on
methadone to 30 mg/d (MEDD 138 mg) and then switched over
to sublingual buprenorphine/naloxone (although did not state her
dose). Alice reported feeling very well on this medication; she had
no drug cravings, was clear minded, and had no knee pain. Alice
had never heard of nor been offered naltrexone.
Alice recognized that knowledge of WISP might have helped
her. She said “I think it would havemade it a lot easier… [knowing]
that it’ll actually go away.”
4. Discussion
This case study illustrates that both opioid use and withdrawal
can activate old healed injury site pain, which can increase with
dose escalation and repeated withdrawal events. The timing and
trajectory of WISP in this case is consistent with those of the
development and resolution of OIH, which has also been shown
to be both opioid dose dependent and withdrawal episode
dependent.6,12,14,15 Also, the pronociceptive changes that occur
in OIH combined with catecholamine release and other factors
has been linked with withdrawal-induced hyperalgesia, which in
turn has been shown to last weeks to months in those with OUDs
or on long-term opioid therapy for chronic noncancer
pain.5,26,31,34 For Alice, she displayed generalized skin sensitivity,
indicating she may have developed OIH revealed during
withdrawal because allodynia can comanifest with hyperalgesia.
It is possible that this pain-sensitive state then uncovered
peripheral or central sensitization that resulted from the original
injury but was quiescent under normal circumstances.27,35 Given
that Alice experienced occasional clicking in her knee, it is
possible that she had underlying pathology that was pain free
under normal circumstances.
Perceived intensity and emotional fear of WISP acted as
a barrier to opioid detoxification for Alice. This is in keeping with
other studies showing that anxiety and fear can influence
inflammation and pain perception.23,29
Alice initially presumed that she had a chronic pain condition,
when instead she had WISP and opioid lowering, detoxification
or rotation was needed for the pain to resolve, as can be the
case in OIH.1,3,20 Nonsteroidal anti-inflammatories and gaba-
pentin were among the medications that subjectively helped
relieve her symptoms of WISP consistent with medications
found to relieve WISP and OIH in other studies.1,3,8,27 Pain
during and immediately after opioid detoxification has been
shown by other authors to be a risk factor for reinitiation of opioid
use.24
Table 1
Quotes from Alice’s narrative.
Theme Quote
I—Bodily experience of WISP At the injury site: “It’s a dull, aching, throbbing,
deep tissue pain” and elsewhere: “you could
just even rip your own skin off, like it’s so
uncomfortable.”
II—Emotional experience of WISP In reference to anxiety felt with WISP: “It
terrified me to come off opiates.”
III—WISP affect on opioid use “And that fear would stop people from getting
off of it just because it—it’s almost
unfathomable to think that the pain could even
go away because it’s so chronic…Yeah, it
produces this cyclical nature of not just using it
for addiction, but for pain…The pain
legitimizes the addiction…”
IV—Theories on the etiology of
WISP
“I thought it was arthritis. I thought it was like
degenerative something or other that had
basically come on and come on strong”
WISP, withdrawal-associated injury site pain.
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At the time of the first interview, Alice had decided to initiate
methadone treatment, which has been shown to be equally
efficacious to buprenorphine/naltrexone in the treatment of OUD
in noninjection opioid analgesia users.25 Despite methadone
being a racemic mixture in which one enantiomer is a mu opioid
receptor agonist and one an NMDAr antagonist, OIH can still
develop.7 Interestingly, a high proportion of people with OUDs
report having what they presume is chronic pain, even after
conversion to methadone.7,10,11 Ultimately for Alice, the metha-
done could not control her right knee pain, although helped her
OUD. In her view, Alice benefitted from once daily oral
buprenorphine/naloxone therapy. Both her pain and her addic-
tion were managed. This is consistent with another study
showing a fifty percent drop in pain when converted from high-
dose pharmaceutical grade opioids to buprenorphine, but is in
contrast to a report of patients with previous heroin use still
displaying OIH on buprenorphine.7,9 One is patient self-report,
and the other an experimentally elicited response, which may
account for the difference.
Alice had never been offered naltrexone, which is a reminder
for clinicians to discuss all medication options with patients.
Naltrexone is an antagonist at both mu opioid receptor and
toll-like receptor 4 on microglial cells, which shows mixed results
in preclinical trials to treat OIH, as well as being a treatment for
OUD.1,16,17
Limitations of this study include Alice’s omission of her
buprenorphine/naloxone dose for comparison. Also, it is un-
known if Alice may build symptoms of OIH andWISP overtime on
buprenorphine/naloxone.
5. Conclusion
We present the first detailed description of a case in which both
opioid use and withdrawal could reactivate injury site pain. This
woman’s experience illustrates that the timing, trajectory, and
neuropathic features of WISP reported here are consistent with
those previously reported for the development and resolution of
OIH, possibly linking these phenomena.
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